AmberGen was awarded a $2 million, 2-year Phase II SBIR grant from NIH-NCI to develop its MALDI-IHC technology for high-plex molecular imaging of cancer tissues.
Company News
AmberGen was awarded a $2 million, 2-year Phase II SBIR grant from NIH-NCI to develop its MALDI-IHC technology for high-plex molecular imaging of cancer tissues.